Orchestra BioMed Holdings (Orchestra BioMed Holdings) FCF Margin % : -2,116.45% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Orchestra BioMed Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Orchestra BioMed Holdings's Free Cash Flow for the three months ended in Mar. 2024 was $-13.12 Mil. Orchestra BioMed Holdings's Revenue for the three months ended in Mar. 2024 was $0.62 Mil. Therefore, Orchestra BioMed Holdings's FCF Margin % for the quarter that ended in Mar. 2024 was -2,116.45%.

As of today, Orchestra BioMed Holdings's current FCF Yield % is -26.51%.

The historical rank and industry rank for Orchestra BioMed Holdings's FCF Margin % or its related term are showing as below:

OBIO' s FCF Margin % Range Over the Past 10 Years
Min: -1674.09 Med: -657.15 Max: 2519.57
Current: -1674.09

During the past 4 years, the highest FCF Margin % of Orchestra BioMed Holdings was 2519.57%. The lowest was -1674.09%. And the median was -657.15%.

OBIO's FCF Margin % is ranked worse than
80.02% of 1046 companies
in the Biotechnology industry
Industry Median: -145.305 vs OBIO: -1674.09

Orchestra BioMed Holdings FCF Margin % Historical Data

The historical data trend for Orchestra BioMed Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orchestra BioMed Holdings FCF Margin % Chart

Orchestra BioMed Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-468.56

2,519.57

-845.74

-1,674.09

Orchestra BioMed Holdings Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial							-1,238.49	-1,149.40	-2,458.47	-4,187.40	-2,116.45

Competitive Comparison of Orchestra BioMed Holdings's FCF Margin %

For the Biotechnology subindustry, Orchestra BioMed Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orchestra BioMed Holdings's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Orchestra BioMed Holdings's FCF Margin % falls into.

Orchestra BioMed Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Orchestra BioMed Holdings's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-46.205	/	2.76
	=	-1,674.09 %

Orchestra BioMed Holdings's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-13.122	/	0.62
	=	-2,116.45 %

Orchestra BioMed Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of Orchestra BioMed Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Orchestra BioMed Holdings (Orchestra BioMed Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchestra BioMed Holdings Inc (NAS:OBIO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 Union Square Drive,, New Hope, PA, USA, 18938

Website

https://www.orchestrabiomed.com

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. Orchestra BioMed's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Executives

George Papandreou	officer: See Remarks	C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Eric S Fain	director	ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN MN
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
David P Hochman	director, officer: See Remarks	15 WESTON HILL RD., RIVERSIDE CT 06878
Joshua Aiello	officer: Principal Accounting Officer	150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Yuval Mika	officer: See Remarks	150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Pamela Ann Connealy	director	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Darren Sherman	director, officer: See Remarks	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Rose Eric A Md	director	161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Andrew Lawrence Taylor	officer: Chief Financial Officer	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
William Reed Little	officer: See Remarks	C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Plc Medtronic	10 percent owner	20 ON HATCH, LOWER HATCH STREET, DUBLIN L2 2
Michael Kaswan	officer: Chief Financial Officer	KBL HEALTHCARE ACQUISITION CORP II, 645 MADISON AVENUE, NEW YORK NY 10022
Geoffrey Wade Smith	director	6740 SHADY OAK ROAD, EDEN PRAIRIE MN 55344
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014